ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1446

Golimumab as First, Second or at Least Third Biologic Agent in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Post Hoc Analysis of a Non-Interventional Study in Germany

Klaus Krüger 1, Gerd Burmester 2, Siegfried Wassenberg 3, Astrid Thiele 4 and Matthias Thomas5, 1Medical Centre of Rheumatology, Munich, Germany, 2Charité—University Medicine Berlin, Berlin, Germany, 3Centre of Rheumatology, Ratingen, Germany, 4Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, 5MSD Sharp & Dohme GmbH, Haar, Germany

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: , , ,

Session Information

Date: Monday, November 11, 2019

Session Title: RA – Treatments Poster II: Established Treatments

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The aim of this post hoc analysis is to assess effectiveness of GLM used as first, second, or at least third biologic agent in RA, PsA and AS in a real-life setting.

Methods: Post hoc analysis of the non-interventional, GO-NICE study with RA, PsA and AS patients starting GLM 50mg SC in a real practice setting in Germany, details were shown earlier (1,2). Endpoint measures DAS28, PsARC, and BASDAI are shown as observed.

Results: In 1458 patients with RA, PsA or AS, GLM was administered as first (n=305, 286, 292, respectively), second (n=104, 136, 130), or at least third biologic agent (n=64, 79, 58). In total, 43.0, 30.8, 39.1% of patients with RA, 53.1, 38.2, 34.2% with PsA, and 53.8, 49.2, 41.4% with AS completed the study until month 24. RA pts. (n=473): Baseline DAS28 scores were 5.0, 4.9, 5.1 in 1st, 2nd, and at least 3rd line use of GLM, respectively, and dropped significantly over time in all groups. Remission rates increased to 27.5%, 19.5%, and 14.5% (month 3) to 45.3%, 50.0% and 33.3% after 24 months of treatment, respectively. PsA pts. (n=501): PsARC response was achieved in 76.4%, 51.0% and 50.0% respectively in patients with GLM use as 1st, 2nd, at least 3rd line at 24 months. AS pts. (n=483): Patients with at least 2 previous bDMARDs had higher BASDAI at BL than patients with GLM use in first or second line: 5.7 vs. 5.0, and 4.9. After 24 months of treatment, the mean BASDAI scores decreased significantly (p< 0.001 vs. BL) to 2.1, 2.9, 2.9 in 1st, 2nd, and at least 3rd line use of GLM, respectively.

Conclusion: In this post-hoc analysis of the non-interventional study, Golimumab as first, second or at least third biologic agent were an effective treatment and showed remarkable improvements in clinical parameters DAS28, PsARC, and BASDAI in patients with RA, PsA, and AS.
Significant improvements of DAS28 and BADSAI was arrived after 3 months vs. BL and maintained over 24 months.


ACR Abstract 123_Table

Table: Effectiveness parameters at BL vs month 24 with GLM use as 1st, 2nd, at least 3rd line

Disclosure: K. Krüger, AbbVie, 5, 8, Biogen, 5, 8, BMS, 5, 8, Celgen, 8, Celgene, 5, 8, Hexal, 5, 8, Janssen, 5, 8, Lilly, 5, 8, MSD, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Roche, 5, 8, Sanofi, 5, 8, Sanofi-Aventis, 5, UCB, 5, 8; G. Burmester, AbbVie, 5, 8, Abbvie, 5, 8, AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma., 5, 8, AbbVie Inc., 5, 8, BMS, 5, 8, Eli Lilly, 5, 8, Eli Lilly and Company, 5, Gilead, 5, 8, Gilead Sciences, Inc., 5, 8, Janssen, 5, 8, Lilly, 5, 8, Merck, 5, 8, Merck Shar & Dohme, 5, 8, MSD, 5, 8, Pfizer, 2, 5, 8, Roche, 2, 5, 8, Roche, Sanofi-Genzyme, 5, 8, Sanofi, 5, 8, UCB, 5, 8, Union Chimique Belge, 2, 5, 8; S. Wassenberg, AbbVie, 5, 8, Chugai, 5, 8, Janssen, 5, 8, MSD, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Roche, 5, 8, UCB, 5, 8; A. Thiele, Biogen, 8, Celgen, 8, Chugai, 8, Hexal, 8, Janssen, 8, Lilly, 8, MSD, 8, Novartis, 8, Pfizer, 8, UCB, 8; M. Thomas, MSD Shap & Dohme GmbH Germany, 3, MSD Sharp & Dohme GmbH, Germany, 3.

To cite this abstract in AMA style:

Krüger K, Burmester G, Wassenberg S, Thiele A, Thomas M. Golimumab as First, Second or at Least Third Biologic Agent in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Post Hoc Analysis of a Non-Interventional Study in Germany [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/golimumab-as-first-second-or-at-least-third-biologic-agent-in-patients-with-rheumatoid-arthritis-ra-psoriatic-arthritis-psa-or-ankylosing-spondylitis-as-post-hoc-analysis-of-a-non-in/. Accessed January 23, 2022.

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/golimumab-as-first-second-or-at-least-third-biologic-agent-in-patients-with-rheumatoid-arthritis-ra-psoriatic-arthritis-psa-or-ankylosing-spondylitis-as-post-hoc-analysis-of-a-non-in/